Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
17
CMMB Quote, Financials, Valuation and Earnings
Last price:
$1.90
Seasonality move
:
25.93%
Day range:
$1.73 - $2.15
52-week range:
$1.73 - $9.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.04x
Volume:
138.7K
Avg. volume:
98.7K
1-year change:
-70.83%
Market cap:
$11.6M
Revenue:
--
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMMB
Chemomab Therapeutics Ltd.
|
-- | -$0.04 | -- | -93.69% | $26.50 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.3M | -$0.08 | -7.77% | -9.81% | $6.25 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -206.85% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMMB
Chemomab Therapeutics Ltd.
|
$1.89 | $26.50 | $11.6M | -- | $0.00 | 0% | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.25 | $3.25 | $4M | -- | $0.00 | 0% | 1.41x |
|
CGEN
Compugen Ltd.
|
$1.52 | $6.25 | $142.2M | 55.83x | $0.00 | 0% | 20.31x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.13 | $399.00 | $3.3M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMMB
Chemomab Therapeutics Ltd.
|
-- | 1.362 | -- | 8.98x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMMB
Chemomab Therapeutics Ltd.
|
-- | -$1.9M | -81.61% | -82.89% | -- | -- |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Chemomab Therapeutics Ltd. vs. Competitors
-
Which has Higher Returns CMMB or CANF?
Can-Fite BioPharma Ltd. has a net margin of -- compared to Chemomab Therapeutics Ltd.'s net margin of --. Chemomab Therapeutics Ltd.'s return on equity of -82.89% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMMBChemomab Therapeutics Ltd.-- -$0.28 $11.2M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About CMMB or CANF?
Chemomab Therapeutics Ltd. has a consensus price target of $26.50, signalling upside risk potential of 1302.12%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.25 which suggests that it could grow by 1189.17%. Given that Chemomab Therapeutics Ltd. has higher upside potential than Can-Fite BioPharma Ltd., analysts believe Chemomab Therapeutics Ltd. is more attractive than Can-Fite BioPharma Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CMMBChemomab Therapeutics Ltd.1 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is CMMB or CANF More Risky?
Chemomab Therapeutics Ltd. has a beta of 0.504, which suggesting that the stock is 49.63% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock CMMB or CANF?
Chemomab Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemomab Therapeutics Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMMB or CANF?
Chemomab Therapeutics Ltd. quarterly revenues are --, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Chemomab Therapeutics Ltd.'s net income of -$1.8M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Chemomab Therapeutics Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemomab Therapeutics Ltd. is -- versus 1.41x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMMBChemomab Therapeutics Ltd.-- -- -- -$1.8M CANFCan-Fite BioPharma Ltd.1.41x -- -- --
-
Which has Higher Returns CMMB or CGEN?
Compugen Ltd. has a net margin of -- compared to Chemomab Therapeutics Ltd.'s net margin of -369.06%. Chemomab Therapeutics Ltd.'s return on equity of -82.89% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital CMMBChemomab Therapeutics Ltd.-- -$0.28 $11.2M CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About CMMB or CGEN?
Chemomab Therapeutics Ltd. has a consensus price target of $26.50, signalling upside risk potential of 1302.12%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 311.18%. Given that Chemomab Therapeutics Ltd. has higher upside potential than Compugen Ltd., analysts believe Chemomab Therapeutics Ltd. is more attractive than Compugen Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CMMBChemomab Therapeutics Ltd.1 0 0 CGENCompugen Ltd.4 0 0 -
Is CMMB or CGEN More Risky?
Chemomab Therapeutics Ltd. has a beta of 0.504, which suggesting that the stock is 49.63% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock CMMB or CGEN?
Chemomab Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemomab Therapeutics Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMMB or CGEN?
Chemomab Therapeutics Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $1.9M. Chemomab Therapeutics Ltd.'s net income of -$1.8M is higher than Compugen Ltd.'s net income of -$7M. Notably, Chemomab Therapeutics Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemomab Therapeutics Ltd. is -- versus 20.31x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMMBChemomab Therapeutics Ltd.-- -- -- -$1.8M CGENCompugen Ltd.20.31x 55.83x $1.9M -$7M
-
Which has Higher Returns CMMB or NSRX?
Nasus Pharma has a net margin of -- compared to Chemomab Therapeutics Ltd.'s net margin of --. Chemomab Therapeutics Ltd.'s return on equity of -82.89% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMMBChemomab Therapeutics Ltd.-- -$0.28 $11.2M NSRXNasus Pharma-- -- -- -
What do Analysts Say About CMMB or NSRX?
Chemomab Therapeutics Ltd. has a consensus price target of $26.50, signalling upside risk potential of 1302.12%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Chemomab Therapeutics Ltd. has higher upside potential than Nasus Pharma, analysts believe Chemomab Therapeutics Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings CMMBChemomab Therapeutics Ltd.1 0 0 NSRXNasus Pharma0 0 0 -
Is CMMB or NSRX More Risky?
Chemomab Therapeutics Ltd. has a beta of 0.504, which suggesting that the stock is 49.63% less volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CMMB or NSRX?
Chemomab Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemomab Therapeutics Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMMB or NSRX?
Chemomab Therapeutics Ltd. quarterly revenues are --, which are larger than Nasus Pharma quarterly revenues of --. Chemomab Therapeutics Ltd.'s net income of -$1.8M is higher than Nasus Pharma's net income of --. Notably, Chemomab Therapeutics Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemomab Therapeutics Ltd. is -- versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMMBChemomab Therapeutics Ltd.-- -- -- -$1.8M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns CMMB or PHGE?
BiomX, Inc. has a net margin of -- compared to Chemomab Therapeutics Ltd.'s net margin of --. Chemomab Therapeutics Ltd.'s return on equity of -82.89% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital CMMBChemomab Therapeutics Ltd.-- -$0.28 $11.2M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About CMMB or PHGE?
Chemomab Therapeutics Ltd. has a consensus price target of $26.50, signalling upside risk potential of 1302.12%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 18632.39%. Given that BiomX, Inc. has higher upside potential than Chemomab Therapeutics Ltd., analysts believe BiomX, Inc. is more attractive than Chemomab Therapeutics Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CMMBChemomab Therapeutics Ltd.1 0 0 PHGEBiomX, Inc.1 0 0 -
Is CMMB or PHGE More Risky?
Chemomab Therapeutics Ltd. has a beta of 0.504, which suggesting that the stock is 49.63% less volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock CMMB or PHGE?
Chemomab Therapeutics Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemomab Therapeutics Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMMB or PHGE?
Chemomab Therapeutics Ltd. quarterly revenues are --, which are smaller than BiomX, Inc. quarterly revenues of --. Chemomab Therapeutics Ltd.'s net income of -$1.8M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Chemomab Therapeutics Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemomab Therapeutics Ltd. is -- versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMMBChemomab Therapeutics Ltd.-- -- -- -$1.8M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
